ConductScience.org, home

Paper · 36717701

E-cadherin is a biomarker for ferroptosis sensitivity in diffuse gastric cancer.

Minikes AM and 5 others. Oncogene, 2023. Cited by 33 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. E-cadherin is a biomarker for ferroptosis sensitivity in diffuse gastric cancer. Papers, record 36717701. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36717701

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
E-cadherin is a biomarker for ferroptosis sensitivity in diffuse gastric cancer.
PubMed
Journal
Oncogene
PubMed
Year
2023
PubMed
Publication types
Journal Article, Research Support, N.I.H., Extramural
PubMed
Citations, by iCite
33
iCite
Relative citation ratio, by iCite
3.02
iCite
Revised in PubMed
2026-08-31
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Minikes AMAlexander M
2Song YYu
3Feng YYan
4Yoon CChanghwan
5Yoon SSSam S
6Jiang XXuejunhttps://orcid.org/0000-0002-8670-3828

Source PubMed

Topics6

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Stomach NeoplasmsMajor topic
FerroptosisMajor topic
Humans
Cadherins
Biomarkers
Mutation

Source PubMed

Grants4

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
F31 CA247112NCI NIH HHSUnited StatesF31CA247112PubMed and NIHNIH RePORTER
P30 CA008748NCI NIH HHSUnited StatesP30CA008748PubMed and NIHNIH RePORTER
R01 CA204232NCI NIH HHSUnited StatesR01CA204232PubMed and NIHNIH RePORTER
R01 CA258622NCI NIH HHSUnited StatesR01CA258622PubMed and NIHNIH RePORTER

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Erratum in42,660,984Correction: E-cadherin is a biomarker for ferroptosis sensitivity in diffuse gastric cancer.https://conductscience.org/library/papers/42660984

Source PubMed

References37

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
133,538,338Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.CA Cancer J Clin2021https://conductscience.org/library/papers/33538338PubMed
216,489,633Epidemiology of gastric cancer.World J Gastroenterol2006https://conductscience.org/library/papers/16489633PubMed
330,115,886Diffuse Gastric Cancer: A Summary of Analogous Contributing Factors for Its Molecular Pathogenicity.Int J Mol Sci2018https://conductscience.org/library/papers/30115886PubMed
425,184,143E-cadherin and gastric cancer: cause, consequence, and applications.Biomed Res Int2014https://conductscience.org/library/papers/25184143PubMed
517,545,690Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer.JAMA2007https://conductscience.org/library/papers/17545690PubMed
628,760,854Oncogenic KRAS and p53 Loss Drive Gastric Tumorigenesis in Mice That Can Be Attenuated by E-Cadherin Expression.Cancer Res2017https://conductscience.org/library/papers/28760854PubMed
711,602,891Prophylactic total gastrectomy for familial gastric cancer.Surgery2001https://conductscience.org/library/papers/11602891PubMed
831,853,199CDH1 (E-Cadherin) Mutation and Gastric Cancer: Genetics, Molecular Mechanisms and Guidelines for Management.Cancer Manag Res2019https://conductscience.org/library/papers/31853199PubMed
920,719,348Prophylactic total gastrectomy for individuals with germline CDH1 mutation.Surgery2011https://conductscience.org/library/papers/20719348PubMed
1029,445,300Gastric cancer: epidemiology, prevention, classification, and treatment.Cancer Manag Res2018https://conductscience.org/library/papers/29445300PubMed

Cited by23

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 33 citations.

PMIDTitleJournalYearIn PapersSource
42,889,604Hippo pathway in cancer ferroptosis: from mechanism insights to targeted therapies.Front Med (Lausanne)2026https://conductscience.org/library/papers/42889604PubMed
42,789,241Pharmacological targeting of ferroptosis in cancer: mechanisms, tumor immunity, and translational challenges.Pharmacol Rep2026https://conductscience.org/library/papers/42789241PubMed
42,388,205CC16 alleviates PM2.5-induced airway inflammation in asthmatic mice by targeting the E-cadherin-mediated ferroptosis regulatory axis.Curr Res Toxicol2026https://conductscience.org/library/papers/42388205PubMed
42,098,074Genetic mutations governing ferroptosis sensitivity and resistance: a precision approach to cancer therapy.Cell Death Dis2026https://conductscience.org/library/papers/42098074PubMed
42,051,451The DBC1-HIF-1α-PPAR-γ axis regulates Treg cell differentiation to promote myocardial fibrosis in experimental diabetic cardiomyopathy through the paracrine secretion of Areg.Front Endocrinol (Lausanne)2026https://conductscience.org/library/papers/42051451PubMed
41,663,756Cell adhesion molecules as emerging regulators of ferroptosis: mechanisms and therapeutic opportunities in cancer.Apoptosis2026https://conductscience.org/library/papers/41663756PubMed
41,607,787Iron-fueled ferroptosis: a new axis for immunomodulation to overcome cancer drug resistance-from immune microenvironment crosstalk to therapeutic translation.Front Immunol2025https://conductscience.org/library/papers/41607787PubMed
41,535,945Ferroptosis and metastasis: molecular checkpoints, microenvironmental dynamics, and therapeutic opportunities.Mol Cancer2026https://conductscience.org/library/papers/41535945PubMed
41,323,780Molecular Mechanisms and Novel Therapeutics Targeting Ferroptosis in Gastric Cancer: A Literature Review.J Cancer2025https://conductscience.org/library/papers/41323780PubMed
40,837,757Role of circulating tumor DNA methylation in gastric cancer initiation and progression: A comprehensive review.World J Gastrointest Oncol2025https://conductscience.org/library/papers/40837757PubMed

1 to 10 of 23

See all 23 cited by

Genes19

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36717701

GET https://conductscience.org/api/papers/v1/36717701/references?page=2